An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic
Clinical trial NCT04395508 · APPROVED_FOR_MARKETING
Trial details
- NCT number
- NCT04395508
- Sponsor
- Genentech, Inc.
- Status
- APPROVED_FOR_MARKETING
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.